Rats were survived for 7 (n¼5), 14 (n¼5) or 56 (n¼5) days. At euthanasia, necropsy was performed to assess for collateral damage and both kidneys underwent gross and histologic assessment.
INTRODUCTION AND OBJECTIVES: Cryoablation is a minimally invasive modality for the management of small renal cortical neoplasms. Successful ablation is dependent on achieving target temperatures (i.e. -20 C) that result in tumor cell death. However, in most cases no thermal sensing device is deployed to monitor the temperature. We investigated long-term oncological outcomes following cryoablation using Multi-Point Thermal Sensing (MTS) needles, which allow precise temperature determination at four points along the needle.
METHODS: We reviewed 20 cryoablation procedures for renal tumors < 4 cm done between 2005 to 2009; 11 procedures were performed with MTS needles with the goal of obtaining -20 C at the tumor margin, while 9 procedures were done without MTS needles. Patient demographics, tumor characteristics, and operative data were retrieved. Follow up CT or MRI imaging was used to assess recurrence status.
RESULTS: With a mean follow-up of 45 months, none of the 11 MTS patients experienced a recurrence, compared to 4 (44.4%) of the non-MTS patients (p ¼ 0.026). Of the biopsy-confirmed renal cancers, none of the 6 in the MTS group recurred compared to 3 of 6 in the non-MTS group (p ¼ 0.182). Age, gender, tumor size, tumor histopathology, grade, follow-up time, and skin-to-tumor distance were similar between the MTS and non-MTS groups. The MTS group had increased duration of freeze (p ¼ 0.041), increased procedure time (p ¼ 0.020), increased number of cryoprobes placed in order to achieve the targeted temperature (p ¼ 0.049), and a greater ratio of cryoprobes used per cm tumor (p ¼ 0.003).
CONCLUSIONS: Using MTS needles, precise target temperatures could be determined during cryoablation of renal tumors. The use of MTS needles was associated with improved oncological outcomes. (MW) but few data are available to evaluate treatment for tumors 4 -7 cm in size. The purpose of this study was to evaluate safety, feasibility, and oncologic efficacy for consecutive biopsy-proven clinical T1b RCC treated with MW ablation. METHODS: Thirty-five biopsy-proven cT1b RCC in 34 consecutive patients (19M/15F, median age 66, IQR: 62.5 -66.0) from May 2012 and October 2016. Patient and procedural data were collected including body mass index (BMI), comorbidities, RENAL nephrometry score. Technical success was evaluated with immediate contrast enhanced post-procedural imaging. Local tumor progression, incidence of complications, and changes in renal function were assessed at follow-up. The Kaplan-Meier method was used for survival analysis.
Source of
RESULTS: Median tumor diameter and nephrometry score were 4.5 cm (IQR: 4.2 -5.1) and 8.0 (IQR: 8.0 -9.0), respectively. Median Charlson Co-Morbidity Index was 5.0 (IQR: 4.0 -7.0). Clear cell RCC histology represented 33/35 (94%) tumors (1 Chromophobe and 1 Papillary Type 2 RCC). There was no significant change in eGFR (p ¼ 0.963). There were 5 (14.7%) high-grade (Clavien-Dindo III-IV) procedure-related complications. Post-operatively one patient developed urosepsis, one developed a urinoma requiring stent placement, and one developed a retroperitoneal hematoma. The remaining two complications were related to the anesthetic. Of 25 patients with followup imaging available, the median duration of imaging and clinical follow-up was 17.0 months (IQR ¼ 8.5 -26.0) and 20.7 months (IQR ¼ 13.9 -27.6), respectively. Immediate technical success was achieved for 33/35 (94%) tumors. There were 2 patients with difficulty visualizing residual enhancing tumor during initial ablation that required repeat ablation. Local tumor recurrence occurred in 1 (2.8%) patient at 26.3 months. The 3 treatment failures were successfully treated with salvage microwave ablation conferring a secondary efficacy of 100%. Estimated 3-yr local progression-free survival, cancer specific survival and overall survival were 83%, 100% and 76%, respectively. CONCLUSIONS: Conclusion: Percutaneous MW ablation is feasible and safe for clinical T1b RCC. Long-term follow-up is needed to establish oncologic efficacy.
Source of Funding: None
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LONG-TERM OUTCOME DATA FROM 47 TREATED RENAL MALIGNANCIES WITH MRI-GUIDED AND MONITORED LASER ABLATION: A SINGLE CENTER STUDY Sherif Nour*, Kareem Elfatairy, Debra Weber, Melinda Lewis, Viraj Master, Atlanta, GA INTRODUCTION AND OBJECTIVES: Percutaneous ablation has become a viable treatment option for localized renal malignancy. MRI guidance has shown an added value for intraprocedural confirmation of complete ablation, potentially reducing the incidence of recurrence. The aim of this study is to report the long term local control data associated with in-bore MRI-guided laser ablation of renal malignancies.
METHODS: 34 patients (18M, 16F, age¼29-88y) with 47 renal masses underwent biopsies followed by MRI-guided laser ablations. A laser fiber with 15mm diffusing tip encased in 5.5 F cooling catheter (Visualase, Texas, USA) was introduced into the target lesion. A test dose of diode laser energy (980nm, 30sec, 9W) was applied to verify location of ablation nidus. Subsequently, ablative energy dose was delivered (27W cycles of 90-240 sec) with treatment endpoint based realtime thermal monitoring of ablation. Fiber repositioning for additional ablation was conducted as needed.
RESULTS: Biopsies showed 1 renal metastasis from lung cancer and 46 RCCs (23 clear, 11 papillary, 2 chromophobe, 7 oncocytic, 1 poorly differentiated, 2 not specified). Tumor sizes were 0.7-4.5 cm (17 upper, 10 lower, 19 midpole). 11 patients (30%) had a single kidney, 6 patients (18%) had prior partial nephrectomy, and 2 lesions were recurrent after cryoablation. Access to desired part of kidney was feasible in all cases. The flexible nature of laser fibers eliminated the complexity of handling bulky ablation probes. Short ablation cycles facilitated accurate temperature mapping. 9 smallmoderate self-limited perinephric hematomas and 1 delayed abscess occurred. Otherwise, no complications were encountered. Median follow-up was 24 months (max ¼ 56 months). No residual or recurrent neoplasms were identified.
CONCLUSIONS: Interactively guided renal ablations performed within an interventional MRI suite are safe and well-tolerated. Data indicate reliable local tumor control with 0% recurrence rate over extended follow-up durations. Efficacy is likely related to improved visualization of tumor margins and temperature sensitivity of MRI allowing refined ablation procedures tailored to tumor response rather than following standard pre-determined ablation parameters.
